- Home
- WM vs GSK Comparison
WM vs GSK Comparison
Compare WM & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WM
- GSK
- Stock Information
- Founded
- WM 1968
- GSK 1715
- Country
- WM United States
- GSK United Kingdom
- Employees
- WM N/A
- GSK N/A
- Industry
- WM Environmental Services
- GSK Biotechnology: Pharmaceutical Preparations
- Sector
- WM Utilities
- GSK Health Care
- Exchange
- WM Nasdaq
- GSK Nasdaq
- Market Cap
- WM 90.3B
- GSK 77.1B
- IPO Year
- WM 1988
- GSK N/A
- Fundamental
- Price
- WM $230.03
- GSK $40.08
- Analyst Decision
- WM Buy
- GSK Hold
- Analyst Count
- WM 20
- GSK 2
- Target Price
- WM $252.72
- GSK N/A
- AVG Volume (30 Days)
- WM 1.9M
- GSK 3.9M
- Earning Date
- WM 07-28-2025
- GSK 07-30-2025
- Dividend Yield
- WM 1.44%
- GSK 4.04%
- EPS Growth
- WM 7.17
- GSK N/A
- EPS
- WM 6.74
- GSK 1.13
- Revenue
- WM $23,950,000,000.00
- GSK $43,336,073,439.00
- Revenue This Year
- WM $19.05
- GSK $5.56
- Revenue Next Year
- WM $5.93
- GSK $5.08
- P/E Ratio
- WM $34.13
- GSK $35.39
- Revenue Growth
- WM 14.18
- GSK 0.59
- 52 Week Low
- WM $199.69
- GSK $31.72
- 52 Week High
- WM $242.58
- GSK $44.67
- Technical
- Relative Strength Index (RSI)
- WM 50.53
- GSK 62.93
- Support Level
- WM $223.87
- GSK $36.75
- Resistance Level
- WM $237.27
- GSK $39.33
- Average True Range (ATR)
- WM 3.63
- GSK 0.57
- MACD
- WM -0.43
- GSK 0.29
- Stochastic Oscillator
- WM 51.11
- GSK 87.62
About WM Waste Management Inc.
WM ranks as the largest integrated provider of traditional solid waste and medical waste services in the United States, operating 262 active landfills, about 506 solid and medical waste transfer stations, and 105 recycling facilities. The company serves residential, commercial, industrial, and medical end markets and is also a leading recycler in North America.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.